Consensus for the Clinical Utility of Brivaracetam in Indian Patients - Survey Results of the INCLUDE Collaborative Group
Abstract number :
V.079
Submission category :
7. Anti-seizure Medications / 7E. Other
Year :
2021
Submission ID :
1825856
Source :
www.aesnet.org
Presentation date :
12/9/2021 12:00:00 PM
Published date :
Nov 22, 2021, 06:50 AM
Authors :
Rajesh Iyer, DM - Vikram Hospital, Bangalore; Rajashekar Reddi, DM - Max Hospital; Jayanti Mani, DM - Kokilaben Dhirubhai Ambani Hospital, Mumbai; rakesh Singh, DM - Jupiter Hospital, Mumbai; Vinay Agarwal, DM - Pragati Hospital, Bareilly, Uttar Pradesh; shalin Shah, DM - ANSA Clinic, Ahmedabad; Sudhir Kumar, DM - Apollo Hospitals, Hyderabad; s Vinoth Kanna, DM - Saveetha Medical College, Chennai; joydeep Biswas - Ruby General Hospital, Kolkata; Soumik Sarkar - IQ City Medical College, Durgapur
Rationale: We conducted a nationwide perception mapping exercise to understand and draw consensus for clinical utility of brivaracetam in everyday clinical practice.
Methods: 317 thought leaders in neurology were invited through whatsapp and email, to respond to a structured questionnaire, developed through a customised technological virtual response system from March 24-April 30, 2021. Anonymised data were analysed by using GraphPad software version 8.4.3.
Results: Mean experience, across 250 respondents, was 13 years (SD 9.3, 95% CI 11-14). Cumulative man-years experience was 3128 years. Amongst the Newer Antiepileptic Drugs (AEDs), 43.6 % (n=109), 49.6% (n=124), 36.8% (n=92), 34% (n=85) ranked brivaracetam as the most preferred for safety, ease of titration, efficacy, potential as an efficacious monotherapy agent, respectively. Brivaracetam has a wide therapeutic window, for higher completion rates for higher doses and its higher level of evidence has created impact for the reason to choose brivaracetam was agreed/ strongly agreed by 86.8% (n=217) and 94.4 % (n=236), respectively. The patients in whom brivaracetam is initiated, 71.6% (n=179), reported that they are already on 1-2 AEDs and the duration of epilepsy is less than 10 years as reported by 84.4 % (n=211). Favourable tolerability was the most important reason for choice for brivaracetam in Indian patients with uncontrolled focal epilepsy by 63.2 % (n=158). 88 % (n=220) opined that patients were satisfied with brivaracetam
Conclusions: Virtual expert nation-wide consensus mapping exercise revealed favourable agreement for utilization of brivaracetam in Indian patients which is in concurrence with the emerging evidence for its favourable tolerability and efficacy
Funding: Please list any funding that was received in support of this abstract.: None.
Anti-seizure Medications